Home/Drugs/Fresolimumab

Fresolimumab

fresolimumab

Phase 2a

Sponsor: Sanofi / Genzyme

Indication: FSGS / DKD

Mechanism of Action

Anti-TGF-beta monoclonal antibody

Target: TGF-β

Clinical Information

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT01284322

Phase:PHASE1Org:Boston University

COMPLETED

Relevant Publications (PubMed)

No recent publications found for fresolimumab.

Validated Models

This drug has been validated in the following preclinical models: